SCHEMBL10004018

SCHEMBL10004018

CCc1nc2c(cc1NC(=O)c1ccc(F)cc1)c(OCC(F)(F)F)c(C(=O)O)n2C

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 1/20 0.41
▸ HPGD P15428 1/20 0.38
▸ POLB P06746 1/20 0.38
▸ MRGPRX1 Q96LB2 2/20 0.37
▸ LMNA P02545 2/20 0.37
▸ KDM4E B2RXH2 1/20 0.37
▸ MCHR1 Q99705 1/20 0.37
▸ P2RY14 Q15391 1/20 0.36
▸ MAPT P10636 1/20 0.36
▸ THRB P10828 1/20 0.36
▸ KCNK2 O95069 1/20 0.36
▸ TRPA1 O75762 1/20 0.36
▸ KMT2A Q03164 3/20 0.36
▸ MEN1 O00255 2/20 0.36
▸ CSNK1D P48730 1/20 0.36
▸ CSNK1E P49674 1/20 0.36
▸ PPARG P37231 1/20 0.35
▸ NPC1 O15118 2/20 0.35
▸ RAB9A P51151 2/20 0.35
▸ CYP1A2 P05177 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10003404 0.93 HTT (0.40) ALDH1A1HPGDMRGPRX1LMNAKDM4E
SCHEMBL10003167 0.92 F10 (0.40) ALDH1A1HPGDMRGPRX1LMNAMAPT
SCHEMBL10003117 0.92 LMNA (0.42) ALDH1A1HPGDPOLBLMNAKDM4E
SCHEMBL10003062 0.91 LMNA (0.46) ALDH1A1HPGDPOLBLMNAKDM4E
SCHEMBL10003568 0.91 NPC1 (0.44) ALDH1A1HPGDLMNAKDM4EMAPT
SCHEMBL10003069 0.91 SMN1; SMN2 (0.41) ALDH1A1POLBMRGPRX1LMNAKDM4E
SCHEMBL10003080 0.89 ALDH1A1 (0.42) ALDH1A1HPGDPOLBMRGPRX1LMNA
SCHEMBL10003422 0.87 PTK2 (0.41) ALDH1A1HPGDMRGPRX1LMNAMAPT
SCHEMBL10004202 0.87 ELANE (0.33) HPGDMAPTTRPA1NPC1RAB9A
SCHEMBL10002857 0.86 L3MBTL1 (0.44) ALDH1A1HPGDPOLBMRGPRX1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2471789-B9 FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL (JP) 2015-03-25 — — EP disclosed
EP-2471789-B1 FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL (JP) 2014-09-17 — — EP disclosed
US-8486965-B2 Pyrrolo[2,3-b]pyridine derivative and use thereof for treatment of cancer TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-07-16 — — US disclosed
US-20120220569-A1 FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-08-30 — — US disclosed
EP-2471789-A1 FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2012-07-04 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120220569-A1 FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF SMO, GLI1, SHH ALDH1A1 321/4885HPGD 539/4885POLB 4723/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback